Relapsed Or Refractory B-Cell Malignancies
NRIXNurix TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1a data readout for Zelebrudomide (BTK Degrader) in Relapsed Or Refractory B-Cell Malignancies. The expected timing is based on the latest available company guidance and may change.
07/09/26:- Phase 1 enrollment completed; data review underway for next steps.
Verification
Confirm timing and program details against the company announcement or filing.